Compare UTL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTL | DRTS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.9M | 978.2M |
| IPO Year | 1995 | N/A |
| Metric | UTL | DRTS |
|---|---|---|
| Price | $52.00 | $9.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $56.50 | $8.67 |
| AVG Volume (30 Days) | 101.3K | ★ 1.1M |
| Earning Date | 05-04-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $536,000,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.22 | $699.98 |
| P/E Ratio | $27.85 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $45.11 | $2.87 |
| 52 Week High | $55.08 | $11.62 |
| Indicator | UTL | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 48.94 |
| Support Level | $49.18 | $6.59 |
| Resistance Level | $52.19 | $11.62 |
| Average True Range (ATR) | 1.35 | 0.95 |
| MACD | 0.22 | -0.21 |
| Stochastic Oscillator | 91.32 | 23.37 |
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.